# Pramlintide

> Pramlintide is a synthetic analog of amylin, a hormone co-secreted with insulin by pancreatic beta cells that is deficient in people with diabetes who use insulin therapy. It is approved as an adjunct to mealtime insulin in adults with type 1 or type 2 diabetes who have not achieved adequate glucose control on insulin alone. By mimicking amylin's natural actions, it helps smooth post-meal blood glucose spikes and can support modest weight reduction. It is administered as a separate subcutaneous injection immediately before meals and is never mixed with insulin in the same syringe. It is a prescription-only medication requiring careful insulin dose adjustment to avoid hypoglycemia.

- URL: https://www.lifeconverted.com/peptides/pramlintide
- Also known as: Symlin
- Primary category: Other & Clinical
- Effectiveness rank: #15 in Weight Management; #16 in Other & Clinical
- Evidence level: Well studied
- Route: Subcutaneous (Injected subcutaneously in the abdomen or thigh immediately before major meals; injection site must be separate from insulin injections.)
- Dose range: 15-120 mcg
- Dose tiers: low 15 mcg; moderate 60 mcg; high 120 mcg
- Half-life: Approximately 48 minutes
- Timing: Before meals
- Cycle: Ongoing, continuous use alongside mealtime insulin as long as clinically indicated on, Not typically discontinued while on adjunct insulin therapy unless not tolerated off (Insulin doses (especially rapid/short-acting) are usually reduced by about 50% when starting pramlintide to reduce hypoglycemia risk.)
- Storage: Refrigerate unopened pens/vials at 2-8°C; an in-use pen may be kept at room temperature below 30°C for up to 28 days, protected from light and heat; do not freeze.

## Mechanism of action

Pramlintide slows gastric emptying, which reduces the rate at which glucose from a meal enters the bloodstream. It also suppresses postprandial glucagon secretion from pancreatic alpha cells, reducing hepatic glucose output after meals, and acts on hypothalamic satiety centers to reduce food intake. Together these actions lower after-meal glucose excursions without directly stimulating insulin release.

## Reported benefits

- Reduces post-meal blood glucose spikes when added to mealtime insulin
- Associated with modest reductions in body weight in clinical studies
- May allow for lower total mealtime insulin requirements
- Suppresses inappropriate glucagon secretion after meals

## Reported side effects

- Nausea, especially when starting therapy or after dose increases
- Increased risk of severe hypoglycemia when combined with insulin, usually requiring an insulin dose reduction
- Injection site reactions
- Headache and decreased appetite

## Common protocols

- Adjunct to mealtime insulin in type 1 diabetes
- Adjunct to insulin, with or without oral agents, in type 2 diabetes

## Stacking notes

Always injected separately from insulin, at a different site, and never mixed in the same syringe; oral medications should be taken at least 1 hour before or 2 hours after due to delayed gastric emptying.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer